Fred R Hirsch, MD, PhD
About Me
Fred R. Hirsch, MD, PhD, FASCO is the Ning Zhao Chair and Professor of Medicine (Hematology and Medical Oncology) and Pathology and Executive Director of the Center for Thoracic Oncology at the Icahn School of Medicine at Mount Sinai. He is also Co-Director of the Center of Excellence for Thoracic Oncology and Associate Director of Biomarker Discovery at the Mount Sinai Tisch Cancer Center, a NCI-Designated Comprehensive Cancer Center.
Before joining Mount Sinai, Dr. Hirsch was Professor of Medicine and Pathology at the University of Colorado for 18 years and Chief Executive Officer of the International Association for the Study of Lung Cancer (IASLC) for five years.
Dr. Hirsch has received numerous awards and honors, including the IASLC Mary Matthews Award for Translational Research in Lung Cancer in 2007, the Japanese Lung Cancer Society Merit Award in 2010, the Addario Foundation Lecture Award in 2015, the Wuan Ki Hong Lectureship Award in 2019, and the Heine H. Hansen Award from the European Society of Medical Oncology (ESMO)/ IASLC in 2022.
Dr. Hirsch has contributed to more than 500 publications in peer-reviewed journals. He is an internationally renowned authority on lung cancer treatment and research.
Dr. Hirsch is on X at @Fred_Hirsch
Research Focus
Dr. Hirsch’s career in lung cancer research spans more than 25 years and includes translational research, targeted therapies, and early detection of lung cancer. His research has helped identify and validate prognostic markers for lung cancer outcomes and biomarkers for personalized lung cancer therapies that illustrate how these therapies work and who is most likely to benefit from them.
Language
English
Position
PROFESSOR | Medicine, Hematology and Medical Oncology, PROFESSOR | Pathology, Molecular and Cell Based Medicine
Education
MD, University of Copenhagen
PhD, University of Copenhagen
BA, University of Copenhagen Business School
Research
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Hirsch has not yet completed reporting of Industry relationships.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.